SmithKline Memric not associated with liver toxicity, researcher tells Alzheimer's Association.

Executive Summary

SMITHKLINE MEMRIC DOES NOT HAVE LIVER TOXICITY OF TACRINE, RESEARCHER Steven DeKosky, MD, University of Pittsburgh Medical Center, told an Alzheimer's Association meeting in New York City Feb. 5. DeKosky reported that Memric, formerly known as SB 202026, is in Phase III studies. Memric, like Warner-Lambert/Roussel Uclaf's milameline and Lilly's xanomeline, is an M1 receptor agonist, DeKosky observed. "None of these" muscarinic agonists "have the liver toxicity of tacrine" (Warner-Lambert's reversible cholinesterase inhibitor Cognex), he reported.